Dysplastic nevus


A dysplastic nevus or atypical mole is a nevus whose appearance is different from that of common moles. In 1992, the NIH recommended that the term "dysplastic nevus" be avoided in favor of the term "atypical mole". An atypical mole may also be referred to as an atypical melanocytic nevus, atypical nevus, B-K mole, Clark's nevus, dysplastic melanocytic nevus, or nevus with architectural disorder.
Dysplastic nevi often grow to larger than ordinary moles, and may have irregular and indistinct borders. Their color may not be uniform, and may range from light pink to very dark brown. They usually begin flat, but parts may be raised above the skin surface. See ABCDE and "ugly duckling" characteristics below.
Dysplastic nevi can be found anywhere, but are most common on the trunk in men, and on the calves in women.
There is some controversy in the dermatology community as to whether or not the "dysplastic"/"atypical" nevus exists. Some have argued that the terms "dysplastic" and "atypical" only refer to diagnostic uncertainty, as opposed to biologic uncertainty, and that the lesion is either a nevus or melanoma from the very beginning, as opposed to some kind of "premalignant stage"; it is only the clinician who is unsure. Some have also argued that even if such nevi do exist, studies have shown that clinicians are unable to reliably identify them anyway, meaning there is no point to even using the concept.

Cancer risk

As seen in Caucasian individuals in the United States, those with dysplastic nevi have a lifetime risk of developing melanoma of greater than 10%, compared to less than 1% for those without any dysplastic nevus.

Precaution for individuals with dysplastic nevi

Although there are limited data to support its efficacy, skin self-examination is frequently recommended for preventing melanoma or for early detection of existing tumors. Examination by a dermatologist has been shown to be beneficial for early melanoma detection. Some dermatologists recommend that an individual with either histologic diagnosis of dysplastic nevus, or clinically apparent atypical moles should be examined by an experienced dermatologist with dermatoscopy once a year.
The abbreviation ABCDE has been useful for helping health care providers and laypersons remember the key characteristics of a melanoma. Changes should be brought to the attention of a dermatologist.
A popular method for remembering the signs and symptoms of melanoma is the mnemonic "ABCDE":
The E is sometimes omitted, as in the ABCD guideline. A weakness in this system is the D. Many melanomas present themselves as lesions smaller than 6 mm in diameter. An astute physician will examine all abnormal moles, including ones less than 6 mm in diameter. Unfortunately for the average person, many seborrheic keratoses, some lentigo senilis, and even warts may have ABCD characteristics, and cannot be distinguished from a melanoma without a trained eye or dermatoscopy.
A recent and novel method of melanoma detection is the "Ugly Duckling Sign". It is simple, easy to teach, and highly effective in detecting melanoma. Simply, correlation of common characteristics of a person's skin lesion is made. Lesions which greatly deviate from the common characteristics are labeled as an "Ugly Duckling", and a dermatologist exam is required. The "Little Red Riding Hood" sign suggests that individuals with fair skin and light colored hair might prove more challenging. These fair-skinned individuals often have lightly pigmented or amelanotic melanomas which will not present with easy to observe color changes and variation in colors. The borders of these amelanotic melanomas are often indistinct, making visual identification without a dermatoscope very difficult. A dermatoscope must be used to detect "ugly ducklings" among those with light skin or blonde/red hair.
People with a personal or family history of skin cancer or of dysplastic nevus syndrome should see a dermatologist at least once a year to be sure they are not developing melanoma.

Biopsy

When an atypical mole has been identified, a skin biopsy takes place in order to best diagnose it. Local anesthetic is used to numb the area, then the mole is biopsied. The biopsy material is then sent to a laboratory to be evaluated by a pathologist. A skin biopsy can be a punch, shave, or complete excision. The complete excision is the preferred method, but a punch biopsy can suffice if the patient has cosmetic concerns and the lesion is small. A scoop or deep shave biopsy is often advocated, but should be avoided due to risk of a recurrent nevus, which can complicate future diagnosis of a melanoma, and the possibility that resulting scar tissue can obscure tumor depth if a melanoma is found to be present and re-excised.
Most dermatologists and dermatopathologists use a system devised by the NIH for classifying melanocytic lesions. In this classification, a nevus can be defined as benign, having atypia, or being a melanoma. A benign nevus is read as having no cytologic or architectural atypia. An atypical mole is read as having architectural atypia, and having cytologic atypia. Usually, cytologic atypia is of more important clinical concern than architectural atypia. Usually, moderate to severe cytologic atypia will require further excision to make sure that the surgical margin is completely clear of the lesion.
The most important aspect of the biopsy report is that the pathologist indicates if the margin is clear, or if further tissue is required. If this is not mentioned, usually a dermatologist or clinician will require further surgery if moderate to severe cytologic atypia is present – and if residual nevus is present at the surgical margin.

Dysplastic nevus syndrome

"Dysplastic nevus syndrome" refers to individuals who have high numbers of benign moles and also have dysplastic nevi. A small percent of these individuals are members of melanoma kindreds. Inherited dysplastic nevus syndrome is an autosomal dominant hereditary condition. Dysplastic nevi are more likely to undergo malignant transformation when they occur among members of melanoma families. At least one study indicates a cumulative lifetime risk of nearly 100% in individuals who have dysplastic nevi and are members of melanoma kindreds.
Roughly 70% of melanomas arise "de novo" on clear skin growth, whereas the rest arise within atypical moles. Those with dysplastic nevi have an elevated risk of melanoma. Such persons need to be checked regularly for any changes in their moles and to note any new ones. In 40-50% of cases, the disorder has been linked with germline mutations in the CDKN2A gene, which codes for p16.

Additional images